Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients

Inclusion Criteria:Patients must meet all of the following inclusion criteria in order to be entered into the study: * Age 20 or older. * Patient has signed informed consent. * Patient must have a diagnosis of hepatocellular cancer confirmed by AASLD and at least one of the following method: * Magnetic resonance imaging (MRI) with early enhancement and delayed enhancement washout of at least one solid liver lesion \> 1 cm. * Contrast enhanced computed tomography (CT) with early enhancement and delayed enhancement washout of at least one solid liver lesion \> 1 cm. * Histological confirmation is required for lesions with inconclusive features. * Patient must not be suitable for treatment by resection or percutaneous ablation at time of study entry. * Patients not suitable for ablation due to lesion location may be enrolled. * Patients with HCC recurrence but not suitable for resection or ablation maybe enrolled. * Patient MUST be with either BCLC stage B OR C, and meet the following criteria: * Stage Child-Pugh A or B AND * Performance status ECOG ≤ 1 WITH Vascular Invasion or WITHOUT Vascular invasion. * Patient has a life expectancy of at least 6 months. Exclusion Criteria:If patients meet any of the following criteria they may not be entered into the study: * Current or previous treatment with chemo- or radiation therapy or sorafenib or drug-eluting chemoembolization (deTACE). * Patients with concurrent cancer except non-melanomatous skin cancer. * Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive. * Performance status ECOG \> 1. * Child-Pugh Class C. * Occlusive tumor thrombus to the main portal trunk. * Active gastrointestinal bleeding. * Evidence of uncorrectable bleeding diathesis. * Extra-Hepatic spread of the HCC. * Encephalopathy not adequately controlled medically. * Presence of ascites not controlled medically. * Any contraindication for MRI/ CT (eg. metallic implants). * Allergy to contrast media that cannot be managed with prophylaxis. * Any contraindication to arteriography. * Any contraindication for doxorubicin administration. * Any contraindication for hepatic embolization. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior to chemoembolization. Hepatofugal blood flow. Serum creatinine \> 2mg/dL. Other condition deemed exclusionary by physician. Uncorrectable impaired clotting.